Christensen P K, Gall M A, Parving H H
Steno Diabetes Center, Gentofte, Denmark.
Diabetes Care. 2000 Apr;23 Suppl 2:B14-20.
To evaluate and compare the clinical course and prognosis in type 2 diabetic patients with persistent albuminuria, with biopsy-proven diabetic glomerulosclerosis (DG), or with nondiabetic glomerulopathies (NDG).
A kidney biopsy was performed in 34 consecutive type 2 diabetic patients with persistent albuminuria (> or = 300 mg/24 h). Glomerular filtration rate (GFR) (51Cr-EDTA) was determined at least once a year, and albuminuria, arterial blood pressure, and HbA1c were determined every 3-6 months.
The biopsy revealed DG in 26 patients (25 men/1 woman) (DG group), age 52 +/- 2 (mean +/- SEM) years, and NDG in 8 patients (7 men/1 woman) (NDG group), age 54 +/- 3 years. The patients were followed for a median of 7.7 years (range 1.0-14.2). In the DG group, GFR decreased from 82 (24-146) to 38 (2-116) ml.min-1.1.73 m-2 (P < 0.001), with a median rate of decline in GFR of 5.6 (0.3-21.6) ml.min-1.year-1, and in the NDG group, GFR decreased from 107 (89-135) to 90 (17-119) ml.min-1.1.73 m-2 (P < 0.05), with a median rate of decline in GFR of 1.3 (0.3-7.6) ml.min-1.year-1 (P < 0.05 between groups). In the DG group, albuminuria increased from 1.4 (0.3-7.2) to 2.6 (0.1-21.6) g/24 h (P < 0.05) and in the NDG group, decreased from 2.2 (0.8-8.7) to 0.8 (0.2-2.5) g/24 h (P = 0.05). Mean arterial blood pressure (MABP) decreased from 118 +/- 3 to 104 +/- 3 mmHg (P < 0.05) in the DG group, whereas it remained unchanged in the NDG group (106 +/- 3 vs. 105 +/- 3 mmHg). In the DG group, the rate of decline in GFR correlated with systolic blood pressure (r = 0.62, P < 0.001), MABP (r = 0.52, P < 0.01), albuminuria (r = 0.55, P < 0.005), and GFR at entry (r = -0.45, P < 0.05).
Our study demonstrated a more rapid decline in GFR and a progressive rise in albuminuria in type 2 diabetic patients with DG compared with type 2 diabetic patients with NDG.
评估并比较持续性蛋白尿的2型糖尿病患者、经活检证实为糖尿病肾小球硬化症(DG)的患者以及非糖尿病性肾小球病(NDG)患者的临床病程及预后。
对34例持续性蛋白尿(≥300 mg/24 h)的2型糖尿病患者进行肾活检。每年至少测定一次肾小球滤过率(GFR)(采用51Cr-EDTA法),每3 - 6个月测定一次蛋白尿、动脉血压及糖化血红蛋白(HbA1c)。
活检显示26例患者(25例男性/1例女性)为DG(DG组),年龄52±2(均值±标准误)岁;8例患者(7例男性/1例女性)为NDG(NDG组),年龄54±3岁。患者随访时间中位数为7.7年(范围1.0 - 14.2年)。DG组中,GFR从82(24 - 146)降至38(2 - 116)ml·min-1·1.73 m-2(P < 0.001),GFR下降的中位数速率为5.6(0.3 - 21.6)ml·min-1·年-1;NDG组中,GFR从107(89 - 135)降至90(17 - 119)ml·min-1·1.73 m-2(P < 0.05),GFR下降的中位数速率为1.3(0.3 - 7.6)ml·min-1·年-1(两组间P < 0.05)。DG组中,蛋白尿从1.4(0.3 - 7.2)增至2.6(0.1 - 21.6)g/24 h(P < 0.05);NDG组中,蛋白尿从2.2(0.8 - 8.7)降至0.8(0.2 - 2.5)g/24 h(P = 0.05)。DG组平均动脉血压(MABP)从118±3降至104±3 mmHg(P < 0.05),而NDG组保持不变(106±3 vs. 10,5±3 mmHg)。DG组中,GFR下降速率与收缩压(r = 0.62,P < 0.001)、MABP(r = 0.5t,P < 0.01)、蛋白尿(r = 0.55,P < 0.005)及初始GFR(r = -0.45,P < 0.05)相关。
我们的研究表明,与NDG的2型糖尿病患者相比,DG的2型糖尿病患者GFR下降更快,蛋白尿呈进行性增加。